833 abstracts found.



Results filter

Using the National Cancer Data Repository to measure long term clinical outcomes – data from the MRC CR07 trial

Year:

Session type:

Eva Morris1,3, Louise Whitehouse1,3, James Thomas2, Phil Quirke1, Lindsay Thompson2, John Wilkinson3, David Sebag-Montefiore1
1University of Leeds, Leeds, UK, 2MRC Clinical Trial Unit, London, UK, 3Northern & Yorkshire Cancer Registry & Information Service, Leeds, UK

A novel method for the high resolution, genome-wide analysis of DNA damage induced by platinum analogue chemotherapy agents – a technology to aid patient stratification

Year:

Session type:

James Powell1, Mark Bennett1, Raymond Waters1, Simon Reed1
1Institute of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK

Lessons to learn – breast cancer treatment – an institutional experience from a developing country

Year:

Session type:

Nasir Afsar1, Bibi Kulsoom1, Ahmed Mateen2, Saeed Ahmed2, Mahwish Tahseen2, Adeel Ahmed2
1Alfaisal University, Riyadh, Saudi Arabia, 2Karachi Institute of Radiotherapy and Nuclear Medicine, Karachi, Pakistan

A genome-wide study of histone H3 acetylation in response to platinum analogue treatment – can the epigenome provide a novel approach to patient stratification?

Year:

Session type:

James Powell1, Mark Bennett1, Raymond Waters1, Simon Reed1
1Institute of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK

Are patients interested in clinical trials? An update from CancerHelp UK

Year:

Session type:

Claire Connolly1, Liz Woolf1
1Cancer Research UK, London, UK

Prognostic significance of hypoxia-inducible factor-1α and vascular endothelial growth factor expression in patients with diffuse large B-cell lymphoma treated with rituximab

Year:

Session type:

James Powell1, Stefan Dojcinov2, Louise King2, Sue Wosniak2, Stephen Gerry3, Angela Casbard3, Hazel Bailey1, Eve Gallop-Evans1, Tim Maughan4
1Velindre Cancer Centre, Cardiff, UK, 2University Hospital of Wales, Cardiff, UK, 3Wales Cancer Trials Unit, Cardiff, UK, 4Gray Institute for Radiation Oncology & Biology, University of Oxford, Oxford, UK

Anti-HER anibodies encapsulated redispersible nanoparticles of Sugar Based PLGA based Polymeric nanoparticles of Tamoxifen citrate and their cellular uptake and cytotoxicity studies in MCF-7

Year:

Session type:

Aftab Alam1, Sushama Talegaonkar1, Amulya K Panda2, Parsad Adamane2, Dinesh G Goswami2, Zeenat Iqbal1
1Jamia Hamdard, Delhi, India, 2National Institute of Immunology, Delhi, India

Phase III multi-centre, randomised, double-blind, placebo-controlled trial of gefitinib versus placebo in oesophageal cancer progressing after chemotherapy, COG (Cancer Oesophagus Gefitinib)

Year:

Session type:

David R Ferry10, Susan J Dutton1, Wasat Mansoor3, Joyce Thompson4, Mark Harrison5, Haider Abbas10, Asa Dahle-Smith2, Anirban Chatterjee6, Stephen Falk7, Angel Garcia-Alonso9, David Walter Fyfe8, Richard Hubner3, Tina Gamble4, Lynnda Peachey1, Mina Davoudianfar1, Sarah R Pearson1, Patrick Julier1, Janusz Jankowski11, Rachel Midgely1, Russell Petty2
1University of Oxford, Oxford, UK, 2University of Aberdeen, Aberdeen, UK, 3Christie Hospital NHS Foundation Trust, Manchester, UK, 4Birmingham Heartlands Hospital, Birmingham, UK, 5Mount Vernon Cancer Centre, Northwood, London, UK, 6Royal Shrewsbury Hospital, Shrewsbury, UK, 7Bristol Haematology and Oncology Centre, Bristol, UK, 8University Hospitals of Morecombe Bay, Lancaster, UK, 9North Wales Cancer Centre, Glan Clwyd, UK, 10Russells Hall Hospital, Dudley, UK, 11QMUL, London, UK

Busulfan pharmacokinetics following intravenous and oral dosing regimens in high-risk neuroblastoma patients treated on a European trial (HR-NBL-1/SIOPEN)

Year:

Session type:

Gareth Veal1, Laurent Nguyen2, Angelo Paci3, Marcello Riggi2, Magali Amiel2, Dominique Valteau-Couanet3, Peppy Brock4, Ruth Ladenstein5, Gilles Vassal3
1Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK, 2Institut de Recherche Pierre Fabre, Boulogne, France, 3Institut Gustave Roussy, Villejuif, France, 4Great Ormond Street Hospital, London, UK, 5St Anna Children’s Hospital and Children’s Cancer Research Institute, Vienna, Austria

The receptor tyrosine kinase EpHA2 is a poor prognostic marker and a novel target in Kras mutant colorectal cancer

Year:

Session type:

Philip Dunne1, Darragh McArt1, Sonali Dasgupta1, Manuel Salto-Tellez1, Patrick Johnston1, Sandra Van Schaeybroeck1
1Queen's University Belfast, Northern Ireland, UK

Page 25 of 84« First...25...50...Last »